Clinical trials: Vomiting Syndrome
Nausea, Vomiting
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have…
- Trial name
- NAVIGATE (NCT06464926)
- Testing
- Enterra Therapy System
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 148 people
- Sponsor
- Enterra Medical, Inc.
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting
The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients
- Trial name
- NCT00642499
- Testing
- Dronabinol
- Where
- 36 sites in United States
- Volunteers
- 103 people
- Sponsor
- Solvay Pharmaceuticals
Nausea and Vomitting
A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS). The main aims of this study are as follows: To check for side effects from treatment with TAK-951.
- Trial name
- NCT06768658
- Testing
- TAK-951
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Takeda
Myelodysplastic Syndrome, Transfusional Iron Overload
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
The objective of the study is to evaluate and compare the frequency and severity of GI adverse events in different dose administration regimens.
- Trial name
- MACS1574 (NCT01326845)
- Testing
- Deferasirox
- Where
- 10 sites in France, Italy and 2 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry